1. Home
  2. NGNE vs TRVG Comparison

NGNE vs TRVG Comparison

Compare NGNE & TRVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NGNE
  • TRVG
  • Stock Information
  • Founded
  • NGNE 2003
  • TRVG 2005
  • Country
  • NGNE United States
  • TRVG Germany
  • Employees
  • NGNE N/A
  • TRVG N/A
  • Industry
  • NGNE Biotechnology: Pharmaceutical Preparations
  • TRVG EDP Services
  • Sector
  • NGNE Health Care
  • TRVG Technology
  • Exchange
  • NGNE Nasdaq
  • TRVG Nasdaq
  • Market Cap
  • NGNE 325.3M
  • TRVG 278.1M
  • IPO Year
  • NGNE N/A
  • TRVG N/A
  • Fundamental
  • Price
  • NGNE $18.48
  • TRVG $3.39
  • Analyst Decision
  • NGNE Strong Buy
  • TRVG Buy
  • Analyst Count
  • NGNE 7
  • TRVG 4
  • Target Price
  • NGNE $41.86
  • TRVG $4.50
  • AVG Volume (30 Days)
  • NGNE 110.1K
  • TRVG 118.4K
  • Earning Date
  • NGNE 08-11-2025
  • TRVG 08-05-2025
  • Dividend Yield
  • NGNE N/A
  • TRVG N/A
  • EPS Growth
  • NGNE N/A
  • TRVG N/A
  • EPS
  • NGNE N/A
  • TRVG N/A
  • Revenue
  • NGNE N/A
  • TRVG $592,176,160.00
  • Revenue This Year
  • NGNE N/A
  • TRVG $18.39
  • Revenue Next Year
  • NGNE N/A
  • TRVG $11.42
  • P/E Ratio
  • NGNE N/A
  • TRVG N/A
  • Revenue Growth
  • NGNE N/A
  • TRVG 7.39
  • 52 Week Low
  • NGNE $6.88
  • TRVG $1.60
  • 52 Week High
  • NGNE $74.49
  • TRVG $5.83
  • Technical
  • Relative Strength Index (RSI)
  • NGNE 35.93
  • TRVG 42.58
  • Support Level
  • NGNE $19.59
  • TRVG $3.18
  • Resistance Level
  • NGNE $20.46
  • TRVG $3.53
  • Average True Range (ATR)
  • NGNE 1.23
  • TRVG 0.17
  • MACD
  • NGNE -0.20
  • TRVG -0.01
  • Stochastic Oscillator
  • NGNE 13.37
  • TRVG 26.94

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and All other countries.

Share on Social Networks: